Students working with Protai conducted a research project testing a new cancer drug targeting the KAT6 protein. They compared its potency and specificity across cancer cell lines with and without estrogen receptors, analyzed its effectiveness against a competitor’s inhibitor, and evaluated potential side effects based on company laboratory data.